Warfarin resistance in a patient with short bowel syndrome

Pharmacotherapy

Volumn 18, Issue 3, 1998, Pages 646-649

  Brophy, Donald F ^a   Ford, Susan L ^a   Crouch, Michael A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; COLESTIPOL; COLESTYRAMINE; ERYTHROMYCIN; ESTROGEN; ETHCHLORVYNOL; FENTANYL; GENTAMICIN; GLUTETHIMIDE; GRISEOFULVIN; INTRALIPID; NAFCILLIN; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; RANITIDINE; RIFAMPICIN; SPIRONOLACTONE; SUCRALFATE; VANCOMYCIN; VITAMIN K GROUP; WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; CASE REPORT; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALABSORPTION; MALE; ORAL DRUG ADMINISTRATION; PARENTERAL NUTRITION; SHORT BOWEL SYNDROME;

ADULT; ANTICOAGULANTS; DRUG RESISTANCE; HUMANS; INTERNATIONAL NORMALIZED RATIO; INTESTINAL ABSORPTION; MALE; RECURRENCE; SHORT BOWEL SYNDROME; THROMBOPHLEBITIS; WARFARIN;

EID: 0031969586     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Hirsch J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 1995;108(4)(suppl): 231S-46.
2. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995;108(4)(suppl): 335S-51.
3. Anonymous. Warfarin resistance in a patient with short bowel syndrome. Nutr Rev 1987;45(7):208-11.
4. Majerus PW, Broze GJ, Miletich JP, Tollefsen DM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Limbird LE, Molinoff PB, eds. The pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 1996:1341-59.
5. Hulse ML. Warfarin resistance: diagnosis and therapeutic alternatives. Pharmacotherapy 1996;16(6):1009-17.
6. Lutomski DM, Lafrance RJ, Bower RH, Fischer JE. Warfarin absorption after massive small bowel resection. Am J Gastroenterol 1985;80(2):99-102.
7. Kearns RJ, O'Reilly RA. Bioavailability of warfarin in a patient with severe short bowel syndrome. J Parenteral Enteral Nutr 1986;10(1):100-1.
8. Shetty HGM, Fennerty AG, Routledge PA. Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy. Clin Pharmacokinet 1989;16:238-53.
9. Tatro DS, Olin BR, Hebel SK. Drug interaction facts and comparisons. St. Louis: Kluwer, 1997.
10. Lefrere JJ, Horellou MH, Conard J, Samama M. Proposed classification of resistances to oral anticoagulant therapy. J Clin Pathol 1987;40:242.
11. Lutomski DM, Palascak JE, Bower RH. Warfarin resistance associated with intravenous lipid administration. J Parenteral Enteral Nutr 1987;11(3):316-18.
12. Mitchell JF, Maas LC, Barger RC, Gelzayd EA. Successful oral anticoagulant therapy in a patient with short bowel syndrome. Am J Hosp Pharm 1977;34:171-2.
13. Lehman ME, Kolb KW, Barnhart GR, Wagman LD, Barr WH. Warfarin absorption in a patient with short bowel syndrome. Clin Pharm 1985;4:325-6.
14. Owens JP, Mirtallo JM, Murphy CC. Oral anticoagulation in patients with short-bowel syndrome. Ann Pharmacother 1990;24:585-9.
15. Roth HC, Rosenthal W, Mandel EE. Lipemia-induced acceleration of intravascular clotting. Proc Soc Exp Biol Med 1959;101:516-19.
16. Amris CJ, Brockner J, Larsen V. Changes in the coagulability of blood during the infusion of Intralipid. Acta Chir Scand 1964;325(suppl):70-7.
17. Cotto MA, Lutomski DM, Palascak JE, Fant WK, LaFrance RJ. Fat emulsion effects on the prothrombin time in warfarin anticoagulated patients: an in vitro study. J Parenteral Enteral Nutr 1990;14:201-3.
18. MacLaren R, Wachsman BA, Swift DK, Kuhl DA. Warfarin resistance associated with intravenous lipid administration: discussion of propofol and review of the literature. Pharmacotherapy 1997;17(6).T331-7.